This clinical trial is focused on studying a condition known as Dravet Syndrome, which is a rare form of epilepsy that begins in infancy and is characterized by frequent and prolonged seizures. The study aims to evaluate a new treatment called Bexicaserin, also known by its code name LP352. This treatment is provided as an oral solution, which means it is taken by mouth. The trial will compare the effects of Bexicaserin to a placebo to determine its effectiveness in reducing seizures in both children and adults with Dravet Syndrome.
The purpose of the study is to assess how well Bexicaserin works in reducing the number of countable motor seizures, which are specific types of seizures that can be measured. Participants in the study will receive either Bexicaserin or a placebo, and their seizure activity will be monitored over time. The study will also look at the safety and tolerability of the treatment, which means checking for any side effects or adverse reactions that might occur.
Throughout the study, participants will undergo regular check-ups, including physical examinations and tests like Electrocardiograms (ECGs), which measure heart activity. Other assessments will include monitoring vital signs, growth parameters like height and weight, and responses to questionnaires about health and well-being. The study is designed to provide valuable information about the potential benefits and risks of using Bexicaserin for treating Dravet Syndrome.
Belgium 
Czechia 
Denmark 
Finland 
France 
Germany 
Italy 
Latvia 
Portugal 
Spain 
The Netherlands 
